ライフサイエンスコーパス: regulatory B-cell

1 st that the cell of origin of CLL might be a regulatory B cell.

2 optimal functioning of human IL-10 producing regulatory B cells.

3 at express Foxp3, suggesting an induction of regulatory B cells.

4 ism that appears to involve the induction of regulatory B cells.

5 duced expansions of cells with phenotypes of regulatory B cells.

6 -cell immune responses, and have been termed regulatory B cells.

7 unique and previously undescribed subset of regulatory B cells.

8 ified and compared with previously described regulatory B cells.

9 B cells represent a unique subset of potent regulatory B cells.

10 erm remission through expansion of Tregs and regulatory B cells.

11 such as through the production of IgG or as regulatory B cells.

12 lasts/plasma cells, memory cells, and immune regulatory B cells.

13 precursors from the bone marrow to generate regulatory B cells.

14 und to be active in vivo in PanIN-associated regulatory B cells.

15 like cells to generate metastasis-supporting regulatory B cells.

16 , while negatively associated with exhausted/regulatory B cells.

17 o molecules described as highly expressed by regulatory B cells.

18 ferentiation and restrained the expansion of regulatory B cells.

19 IL-21 can induce both plasma cells and regulatory B cells.

20 late the preferential accumulation of T2-MZP regulatory B cells.

21 IL-10(+) (B1a) regulatory B cells accumulate selectively in melanomas,

22 Regulatory B cells acquire the ability to produce IL-10

23 long-lived plasma cells, memory B-cells, and regulatory B-cells, along with their various differentia

24 erall B cell function; however, tumor-evoked regulatory B cells also regulate MDSC function, suggesti

25 t data highlight the role of IL-10-producing regulatory B cells and "protective" antibodies that like

26 re associated with an increased frequency of regulatory B cells and augmented B cell-derived IL-10 pr

27 thors show that the IL-12p35 subunit induces regulatory B cells and can be used therapeutically to li

28 review, we make a case for the existence of regulatory B cells and discuss the possible developmenta

29 ed adjuvanted vaccine maintains intratumoral regulatory B cells and fails to improve antitumor respon

30 HFD reduced the number of regulatory B cells and IL-10 production in the liver of

31 age polarization, the production of IL-10 by regulatory B cells and IL-27-mediated suppression of lym

32 mmune responses in cancer can be mediated by regulatory B cells and is often a result of increased pr

33 Regulatory B cells and myeloid-derived suppressor cells,

34 Besides T cells, MDSCs promote regulatory B cells and suppress overall B cell function;

35 s therapeutic actions in restoring levels of regulatory B cells and suppressing neutrophil and mast c

36 Signals that lead to the expansion of regulatory B cells and the spectrum of their functional

37 Mechanisms of regulatory B cells and their cell therapy potential are

38 ly higher blood tolerogenic dendritic cells, regulatory B cells, and cell phenotypes correlating with

39 oid-derived suppressor cells, CD1d(hi)CD5(+) regulatory B cells, and Th17 cells.

40 Principally a failure of IL-10 producing regulatory B cells as demonstrated through functional ex

41 ts the potential relevance of transitional ("regulatory") B cells as a biomarker and therapeutic inte

42 and cells with phenotypic characteristics of regulatory B cells, as well as a long-term dominance in

43 Expression of regulatory B-cell-associated surface markers, interleuki

44 idence has demonstrated that IL-10-producing regulatory B cells (B(regs)) are specialized to suppress

45 e model of MS, adoptive transfer of IL-10(+) regulatory B cells (B(regs)) has been shown to reverse E

46 clerosis, that the transfusion of autologous regulatory B cells (B(regs)) is able to ameliorate, cure

47 Regulatory B cells (B-reg) produce IL-10 and suppress in

48 ove the acute expansion of a small subset of regulatory B cells (B10 cells) that potently suppress in

49 Human and mouse regulatory B cells (B10 cells) with the ability to expre

50 of cGVHD and support future investigation of regulatory B cell-based therapy in the treatment of this

51 -regulating mechanism by which they modulate regulatory B cell (Breg) function is not well understood

52 The suppressive effects are driven by a regulatory B cell (Breg) population that functions, prim

53 Impaired regulatory B cell (Breg) responses are associated with s

54 Regulatory B cells (Breg cells) differentiate in respons

55 Regulatory B cells (Breg) are a heterogenous population

56 Regulatory B cells (Breg) are instrumental in protecting

57 at a similar process may operate to modulate regulatory B cells (Breg).

58 late T-cell immune responses, and are termed regulatory B cells (Breg).

59 B-cells in the TME differentiate into regulatory B cells (Bregs) (IL-10(+)CD1d(+)CD5(+)CD138(+

60 Regulatory B cells (Bregs) ameliorate autoimmune disease

61 We identified regulatory B cells (Bregs) and regulatory myeloid cells

62 Regulatory B cells (Bregs) and tolerogenic dendritic cel

63 The interest in regulatory B cells (Bregs) began in the 1970s with the e

64 Regulatory B cells (Bregs) contribute to immune regulati

65 Conversely, IL-10 producing regulatory B cells (Bregs) exert immunosuppressive funct

66 decades ago, a subset of B cells denoted as regulatory B cells (Bregs) have elicited interest throug

67 Regulatory B cells (Bregs) have shown promise as anti-re

68 A subset of regulatory B cells (Bregs) in mice negatively regulate T

69 To test the relevance of regulatory B cells (Bregs) in the suppression of cutaneo

70 Regulatory B cells (Bregs) modulate immune responses pre

71 Here, we evaluated the influence of regulatory B cells (Bregs) on T-cell cytokines in vitro

72 Although IL-10-producing regulatory B cells (Bregs) play important roles in immun

73 al group of interleukin-10 (IL-10)-producing regulatory B cells (Bregs) that negatively regulate T-ce

74 attributed to relatively rare populations of regulatory B cells (Bregs) that produce anti-inflammator

75 attributed to relatively rare populations of regulatory B cells (Bregs) that produce anti-inflammator

76 roducing B cells represent a major subset of regulatory B cells (Bregs) that suppress autoimmune and

77 oth cytokine expression and number of TIM-1+ regulatory B cells (Bregs) were induced by TIM-1-specifi

78 estigation, elevated CD19(+) CD24(+) CD38(+) regulatory B cells (Bregs) were observed in PBMCs of inv

79 e thymoma TME, CD19+ B cells, CD19+CD5+CD1d+ regulatory B cells (Bregs), CD4+ T cells, and CD4+CXCR5+

80 In addition, a subset of B cells, known as regulatory B cells (Bregs), exhibit immunosuppressive fu

81 One functional B cell subset, regulatory B cells (Bregs), has recently been shown to c

82 the existence of a subset of B lymphocytes, regulatory B cells (Bregs), which modulate immune functi

83 d a profound defect in IL-10 production from regulatory B cells (Bregs).

84 les, IL-10 and PD-L1, two characteristics of regulatory B cells (Bregs).

85 in domain (Tim)-1 identifies IL-10-producing regulatory B cells (Bregs).

86 Interleukin 10 (IL-10)-producing B cells (regulatory B cells [Bregs]) regulate autoimmunity in mic

87 tially suppressive cells, including not only regulatory B cells but also Tregs.

88 strate that IFN-beta therapy requires immune-regulatory B cells by showing that B cell-deficient mice

89 ogenesis of autoimmune diseases, but whether regulatory B cells can be therapeutically induced in hum

90 had reduced frequency of ovalbumin-specific regulatory B cells compared to egg-tolerant infants.

91 , there were no differences in the number of regulatory B cells comparing the two groups of immunized

92 ltogether, these data indicate a compromised regulatory B-cell compartment as an additional defect in

93 Regulatory B cells control inflammation and autoimmunity

94 s through the induction of immunosuppressive regulatory B cells, designated tBregs.

95 Recent studies indicate that regulatory B cells develop in several murine models of c

96 e demonstrated the presence in the spleen of regulatory B cells enriched in the CD24(int)CD38(+)CD27(

97 ssed the putative generation of anti-colitic regulatory B cells following H. diminuta infection.

98 CD19(+), CD5(-), CD1d(-), IgD(hi) regulatory B cells from healthy controls produced IL-10

99 established genetic models for the study of regulatory B cell function and their potential for thera

100 characterization of the mechanisms by which regulatory B cells function has led to the identificatio

101 pt binding to CD80/CD86 induces and promotes regulatory B cell functions by enhancing the ability of

102 The balance between effector and regulatory B cell functions is critical in the maintenan

103 sma cell populations that are enriched for a regulatory B cell gene signature.

104 Granzyme B-expressing regulatory B cells (GraB cells) cells from HIV patients

105 Dysfunction of interleukin-10 producing regulatory B cells has been associated with the pathogen

106 The immunosuppressive function of regulatory B cells has been shown in several murine mode

107 Production of IL-10 by regulatory B cells has been shown to modulate the severi

108 A novel subset of human regulatory B-cells has recently been described.

109 Regulatory B cells have largely been reported as B cells

110 Unlike splenic regulatory B cells, however, these TDLN B cells did not

111 ssed by a large majority of IL-10-expressing regulatory B cells in all major B cell subpopulations, i

112 Here, we elaborate broadly on the history of regulatory B cells in cancer and summarize recent studie

113 shed light on the paradoxical activities of regulatory B cells in early life.

114 In conclusion, GraB cells represent potent regulatory B cells in humans that are phenotypically and

115 on of human and mouse interleukin (IL)-35(+) regulatory B cells in pancreatic cancer.

116 he importance of Itga4 for the generation of regulatory B cells in peripheral immune organs and their

117 ne asthma model illustrate a central role of regulatory B cells in the control of lung function and a

118 We investigated the role of IL-10 and regulatory B cells in the pathogenesis of CHB.

119 s highlighting a protective role of IL-10(+) regulatory B cells in this setting.

120 data showing crosstalk between microglia and regulatory B-cells in the brains of mice infected with T

121 y and inflammation are controlled in part by regulatory B cells, including a recently identified IL-1

122 Immune suppression by regulatory T cells and regulatory B cells is a critical mechanism to limit exce

123 and humans, a rare, but specific, subset of regulatory B cells is functionally characterized by its

124 d to the identification of a novel subset of regulatory B cells known as B10 cells, which regulate im

125 ols, and monitored for the expression of the regulatory B cell markers CD1d, CD24, CD38, and surface

126 IL-10-producing regulatory B cells may represent such a protective B cel

127 s and multiple sclerosis, pentanoate-induced regulatory B cells mediate protection from autoimmune pa

128 pe in stroke and suggest that enhancement of regulatory B cells might have application as a novel the

129 d abundance of immunoregulatory populations (regulatory B cells, myeloid regulatory cells) in lung pa

130 molecule (TIM)-1 broadly identifies IL-10(+) regulatory B cells, no similar markers for Be1 cells hav

131 Neither regulatory B cells nor tolerogenic dendritic cells contr

132 x 10(9) cells/L (P = .001), indicating that regulatory B cells of patients with ITP are functionally

133 The influence of regulatory B cells on airway hyperreactivity (AHR) and r

134 1 expression and high in vivo frequencies of regulatory B cells overexpressing the serine protease gr

135 was the most prominent at inducing IL-10(+) regulatory B cells (P < .05).

136 A specific deficit in regulatory B cells participates to more severe allergic

137 We found that a particular newborn regulatory B cell population (nBreg) negatively regulate

138 These data suggest the existence of a regulatory B-cell population that promotes tolerance via

139 FN-beta treatment increases transitional and regulatory B cell populations, as well as IL-10 secretio

140 eactive B cells and supporting protective or regulatory B cell populations.

141 ften have features of the recently described regulatory B cells producing immunosuppressive IL-10.

142 Abatacept significantly potentiated regulatory B cell regulatory functions by enhancing thei

143 rived regulatory cell populations, including regulatory B cells, regulatory macrophages, tolerogenic

144 se or after differentiating into more mature regulatory B cells remain to be characterized.

145 d functional overlap between these cells and regulatory B cells remains controversial.

146 immunoglobulins produced by IL-10-producing regulatory B cells remains unknown.

147 IgD(hi) regulatory B cells represent a novel regulatory B cell t

148 ed after episodes of inflammation, or if the regulatory B-cell response is subverted.

149 Regulatory B cells restrict immune and inflammatory resp

150 ition, potentially protective CD1d(hi)CD5(+) regulatory B cells show resistance to depletion, and mye

151 ich population by 6 months with an increased regulatory B cell signature.

152 In addition, recent studies of regulatory B cells strongly suggest that Tregs may not h

153 and a rare IL-10-producing CD1d(high)CD5(+) regulatory B cell subset (B10 cells) have been identifie

154 pletion of a rare IL-10-producing CD1dhiCD5+ regulatory B cell subset (B10 cells), since the adoptive

155 paralleled depletion of the IL-10-producing regulatory B cell subset called B10 cells.

156 For clarity, this regulatory B cell subset has been labeled as B10 cells,

157 g B cells have been shown to be an important regulatory B cell subset in humans.

158 The spleen regulatory B cell subset with the functional capacity to

159 dies have identified a novel IL-12-producing regulatory B-cell subset that develops under Th2-mediate

160 However, specific regulatory B cell subsets recently were identified that

161 B cells, there is also mounting evidence for regulatory B cell subsets that may play a protective rol

162 to wildtype (WT) among all major B cell and regulatory B cell subsets.

163 kade did not change other previously defined regulatory B-cell subsets (Breg), including CD5CD1d Breg

164 and IL-10(+)CD19(+)CD5(hi)CD38(int)CD24(int) regulatory B-cell subsets compared to Phl p (all P < .05

165 In allergy, some regulatory B-cell subsets producing IL-10 have been rece

166 IL-10-producing regulatory B cells suppress immune responses, and lack o

167 be abrogated by inactivation of tumor-evoked regulatory B cells (tBreg).

168 We reported previously that tumor-evoked regulatory B cells (tBregs) play an essential role in br

169 IgD(hi) regulatory B cells represent a novel regulatory B cell that may precipitate T cell exhaustion

170 Regulatory B cells that are functionally defined by thei

171 To investigate the potential contribution of regulatory B cells, their frequency was measured directl

172 ciliated cells, it activates human neonatal regulatory B cells, thereby inhibiting immunological res

173 Induction of regulatory B cells was associated with allergen-neutrali

174 Exhausted and regulatory B cells were declined whereas memory B cells

175 Whereas JHT mice have no B cells at all, regulatory B cells were found in the liver of both wild-

176 Ovalbumin-specific regulatory B cells were identified by co-expression of f

177 ILC3s and regulatory B cells were in close connection with each ot

178 IL-10(+) regulatory B cells were increased in season compared to

179 Regulatory B cells were not required for induction of to

180 P3(+), follicular regulatory T, and IL-10(+) regulatory B cells were observed at V6 (all P < .05) and

181 )2A, T follicular helper (Tfh), and IL-10(+) regulatory B cells were quantified by flow cytometry in

182 IL-10(+) regulatory B cells were quantified in peripheral blood b

183 Tonsillar ILC3s and regulatory B cells were visualized with immunofluorescen

184 sets, including B effector 1 (Be1) cells and regulatory B cells, which can promote or inhibit immune

185 e response through the generation of CD19(+) regulatory B cells, which in turn are able to influence

186 we found a reduced frequency of CD24hiCD38hi regulatory B cells with impaired IL-10 production.

187 of cognate B cells into disease-suppressing regulatory B cells, without compromising systemic immuni